Cellectar Biosciences Inc. (CLRB) announced Tuesday morning that its Phase 1b clinical trial of CLR 131, for the treatment of relapsed/refractory multiple myeloma, demonstrated overall survival of 19.4 months.
Cellectar Biosciences has gapped open higher this morning and is now up 0.57 at $3.86 on above average volume. The stock has jumped to a 2-month high.
For comments and feedback contact: editorial@rttnews.com
Business News